Senate to vote on von Eschenbach nomination today

Share this article:
The US Senate is scheduled to consider Andrew von Eschenbach’s nomination to head the FDA today. The Senate has scheduled a procedural vote that requires the support of 60 senators to advance the nomination to a full vote, Reuters reported. Several senators have praised von Eschenbach’s qualifications to lead the agency and his nomination cleared a Senate committee in September. But three Republican Senators have blocked a full Senate vote. Senate Finance Committee Chairman Charles Grassley of Iowa said he opposed a von Eschenbach confirmation vote because the FDA failed to cooperate with his investigation of Sanofi-Aventis’ antibiotic Ketek and related reports of liver failure. Sen. Jim DeMint of South Carolina opposed a vote due to his concerns about the safety of the abortion pill RU-486. Sen. David Vitter of Louisiana said he will oppose a vote until prescription drug imports are legalized. Spokespeople for each of the three senators told Reuters early today they still object to a vote on von Eschenbach’s nomination.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.